Rovensa Group Launches Rovensa Next, a New Global Biosolutions Business Unit to Shape a Sustainable Future for Agriculture
8.2.2023 13:44:00 EET | Business Wire | Press release
Faced with global challenges due to a growing population and climate change, among others, farmers need a solution to feed the planet through healthy and safe solutions. Today, Rovensa Group, a global leader of agricultural inputs for sustainable agriculture, answers that need with Rovensa Next, a new global business unit dedicated to biosolutions for agriculture that aims to give back to the Earth what the Earth gives to us. Rovensa Next makes its debut this week at Fruit Logistica Berlin (Hall 1.2, Stand B-50), the leading trade fair for the fresh fruit industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230208005486/en/
José Alfredo García, Co-COO Rovensa Next, Javier Calleja, incoming CEO Rovensa Group, Eric van Innis, CEO Rovensa Group and Carlos Ledó, Co-COO Rovensa Next (Photo: Business Wire)
Rovensa Next aggregates ten Rovensa Group companies, creating a holistic platform of innovative biosolutions to shape a sustainable future for agriculture and drive its bio-transformation. With this announcement, Agrichembio, Agrotecnología, Idai Nature, Microquimica, MIP Agro, OGT, Oro Agri, Rodel, SDP, and Tradecorp will become part of the new business unit, combining local technical knowledge, innovation and teams that work alongside farmers and distributors in the field to solve their sustainability challenges, with the global expertise and leadership of Rovensa Group.
Eric van Innis, Rovensa Group CEO, stated: “With this flagship project Rovensa Next, and our holistic platform of biosolutions, we are taking a strategic step forward in our goal to be a reference provider of well-balanced and sustainable solutions for agriculture. Farmers and distributors do not need a singular product or a multi-card generalist; they need specialised advisors to help them create a potent strategy that considers their local environment and challenges. Rovensa Next is our answer to our partners’ needs for sustainable crop management that leads to safe and healthy products with better quality and increased yield.”
Betting on sustainability, innovation, and technical expertise, Rovensa Next unites a global network of 30 R&D laboratories, excellence centres, fields, and greenhouses; 14 production plants; more than 84 partnerships with research centres and universities; 100 R&D and innovation specialists; and a dedicated team of more than 850 field expertsi. All of this allows Rovensa Next to be the pioneer on cutting-edge research to create more effective and environmentally friendly biosolutions that don’t compromise on performance or quality.
Carlos Ledó, Co-Chief Operating Officer of Rovensa Next, commented: “With a rising population and a rapidly changing climate, there is a clear need to transform the agricultural sector. The formation of Rovensa Next, consisting of ten brands with entrepreneurship in their DNA, gives us the right talent, know-how, expertise, and innovation to drive the necessary change in agriculture. The time is now for sustainable transformation.”
José Alfredo García, Co-Chief Operating Officer of Rovensa Next, added: “We want to be a trusted partner that helps our customers drive sustainable transformation without compromising on performance and yield output. Our unique value add is our team of field experts that work on the ground with growers to understand their needs and solve their challenges. By uniting all of our local and specialised expertise in various crops and geographical areas into one global portfolio of solutions, we aim to help facilitate, or even kickstart, the bio-transformation for customers, ultimately helping to shape an overall more sustainable future.”
With the new business unit, Rovensa Group anticipates a turnover of more than EUR 1 billion by 2025i. Today’s announcement marks the beginning of the global transition to Rovensa Next followed by local implementation across all countries from July 2023.
For more information, go to www.rovensanext.com
About Rovensa Group
Rovensa Group is a global leader in agricultural solutions for sustainable agriculture. It is a group of companies that develop, manufacture, and commercialise agricultural solutions to help farmers produce safe, healthy and nutritious food for all.
Committed to generating a positive impact through its companies, more than 4,000 employees strive each day to contribute to our mission of feeding the planet. With more than 30 Research and Development (R&D) experimental centres and laboratories across the world, we are leading the change in agriculture through science-led innovation to continuously develop pioneering agricultural inputs to preserve and enhance soil, environmental, and human health. We are providing farmers, spread over 80 countries across the globe, a complementary portfolio of solutions for bionutrition, biocontrol and crop protection to support the transition towards a more well-balanced agriculture, enabling them to grow a larger quantity and higher quality of food with fewer natural resources.
For more information, go to www.rovensa.com
- Rovensa Next figures including ten aggregated companies and the Cosmocel acquisition.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230208005486/en/
Contact information
For further information:
Rovensa Next
Elisa Lipperheide
Global Communication Manager
elisa.lipperheide@rovensanext.com
m. +34 687 111 148
Chelsey Rodowicz
Ogilvy PR
chelsey.rodowicz@ogilvy.com
m. +34 620 035 403
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom